Management ChangeJul 22, 2026, 04:07 PM
Keros Therapeutics CFO Departs; Interim CFO Appointed
AI Summary
Keros Therapeutics announced the resignation of Chief Financial Officer Keith Regnante, effective August 3, 2026, as he pursues other opportunities. Annita Tanini, the company's Corporate Controller and Vice President, Finance, has been appointed interim principal financial officer and principal accounting officer, effective August 4, 2026. Ms. Tanini will receive an annual base salary of $302,300 and is eligible for an annual cash bonus with a target of 30% of her base salary. The company has initiated a search for a permanent CFO.
Key Highlights
- Keith Regnante resigned as CFO of Keros Therapeutics, effective August 3, 2026.
- Annita Tanini appointed interim principal financial officer, effective August 4, 2026.
- Ms. Tanini's annual base salary set at $302,300.
- Ms. Tanini eligible for annual cash bonus target of 30% of base salary.
- Ms. Tanini's severance includes 6 months base salary and COBRA premiums.
- Mr. Regnante's departure was voluntary, not due to disagreements.
- Keros Therapeutics has commenced a search for a new Chief Financial Officer.
Price Impact
More from KROS